Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 100%High 0 · 0%

Annualised relapse rate · patients with relapsing‐remitting multiple sclerosis

Fingolimod 0.5 mg probably leads to lower annualised relapse rate compared with interferon beta‐1a (moderate certainty).

1 finding from 1 review

Fingolimod for relapsing‐remitting multiple sclerosis 2016 · Cochrane Headline outcomes only
Rate ratio 0.48 [0.34, 0.7]
1 study · 860 participants
Moderate